Evidence map›Paper›PMID 36435990›Full record

Trial reportAllergy2023

Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses.

Kirsty Logan, Henry T Bahnson, Alyssa Ylescupidez, Kirsten Beyer, Johanna Bellach, Dianne E Campbell, Joanna Craven, George Du Toit, E N Clare Mills, Michael R Perkin and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes.The journal of allergy and clinical immunology. In practice · 2026
    Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. An Exploratory Analysis of Transcriptional Responses to Peanut Exposure inInternational journal of molecular sciences · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Early-Life Allergen Exposure and Its Influence on Risk of Atopic Disease.The journal of allergy and clinical immunology. In practice · 2025
    Review
  12. Article
  13. Review
  14. Feast for thought: A comprehensive review of food allergy 2021-2023.The Journal of allergy and clinical immunology · 2024
    Review
  15. Risk subgroups and intervention effects among infants at high risk for peanut allergy: A model for clinical decision making.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Primary Prevention of Allergy - Is It Feasible?Allergy, asthma & immunology research · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kirsty LoganDepartment of Women and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK.
Henry T BahnsonImmune Tolerance Network, Benaroya Research Institute, Seattle, Washington, USA.
Alyssa YlescupidezImmune Tolerance Network, Benaroya Research Institute, Seattle, Washington, USA.
Kirsten BeyerCharité Universitätsmedizin Berlin, Berlin, Germany.
Johanna BellachCharité Universitätsmedizin Berlin, Berlin, Germany.
Dianne E CampbellChildren's Hospital at Westmead, Westmead, New South Wales, Australia.
Joanna CravenDepartment of Women and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK.
George Du ToitDepartment of Women and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK.
E N Clare MillsSchool of Biological Sciences, Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.
Michael R PerkinThe Population Health Research Institute, St George's University of London, London, UK.
Graham RobertsUniversity of Southampton and Southampton NIHR Biomedical Research Centre, Southampton, UK.ORCID 0000-0003-2252-1248
Ronald van ReeDepartments of Experimental Immunology and of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Gideon LackDepartment of Women and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK.ORCID 0000-0001-7350-4021

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
Immune Tolerance Network: Type 1 diabetesN01AI15416 · NIAID · UNIVERSITY OF SAN FRANCISCO · PI BLUESTONE, JEFFREY · 2007 to 2013
$276.6M
IMMUNE TOLERANCE NETWORK-266015416-266015416N01AI015416 · NIAID · REGENTS OF THE UNIVERSITY OF C · PI BLUESTONE, JEFFREY A · 2002 to 2006
–
Medical Research Council MC_G1001205NIAID NIH HHS HHSN272200800029CNIAID NIH HHS N01AI15416NIAID NIH HHS UM1 AI109565
6 · The paper itself

Abstract

backgroundThe Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per-protocol (PP) analyses, which can be subject to bias.

objectiveThe aim of this study was to combine individual-level data from the LEAP and EAT trials and provide robust evidence on the bias-corrected, causal effect of early peanut introduction.

methodAs part of the European Union-funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods.

resultsAn intention-to-treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004).

conclusionWe demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.

Indexed as

EczemaPeanut HypersensitivityAllergensArachisChildHumansInfantRisk FactorsAllergenscausal inference analysisearly introductionpeanut allergy prevention

Identifiers

PMID36435990
PMCPMC10202125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.